ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,154.07
0.33%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Akero Therapeutics Inc (AKRO)

  7. Akero Therapeutics Inc (AKRO) Noticias

AKRO

Akero Therapeutics (AKRO)

Akero Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:AKRO
FechaHoraFuenteTítuloSímboloCompañía
10/05/202415:57Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AKROAkero Therapeutics Inc
10/05/202406:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AKROAkero Therapeutics Inc
10/05/202406:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AKROAkero Therapeutics Inc
10/05/202406:00GlobeNewswire Inc.Akero Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
08/05/202406:00GlobeNewswire Inc.Akero Therapeutics to Present at the BofA Securities 2024 Health Care ConferenceNASDAQ:AKROAkero Therapeutics Inc
30/04/202407:00GlobeNewswire Inc.Akero Therapeutics Appoints Scott Gangloff as Chief Technology OfficerNASDAQ:AKROAkero Therapeutics Inc
08/03/202415:02GlobeNewswire Inc.Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional SharesNASDAQ:AKROAkero Therapeutics Inc
07/03/202415:01GlobeNewswire Inc.Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and HepatologyNASDAQ:AKROAkero Therapeutics Inc
06/03/202419:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AKROAkero Therapeutics Inc
06/03/202416:16Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AKROAkero Therapeutics Inc
05/03/202420:13GlobeNewswire Inc.Akero Therapeutics Announces Pricing of Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
05/03/202405:05IH Market NewsAMD Hits Regulatory Roadblock, GitLab’s Stock Tumbles on Disappointing Earnings, and Latest NewsNASDAQ:AKROAkero Therapeutics Inc
04/03/202416:34Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:AKROAkero Therapeutics Inc
04/03/202415:21GlobeNewswire Inc.Akero Therapeutics Announces Proposed Public Offering of Common StockNASDAQ:AKROAkero Therapeutics Inc
04/03/202405:00GlobeNewswire Inc.Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY StudyNASDAQ:AKROAkero Therapeutics Inc
29/02/202415:42Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:AKROAkero Therapeutics Inc
29/02/202407:00GlobeNewswire Inc.Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASHNASDAQ:AKROAkero Therapeutics Inc
29/02/202406:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:AKROAkero Therapeutics Inc
29/02/202406:00GlobeNewswire Inc.Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
13/02/202420:40Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AKROAkero Therapeutics Inc
03/01/202407:15GlobeNewswire Inc.Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:AKROAkero Therapeutics Inc
18/12/202306:00GlobeNewswire Inc.Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY ProgramNASDAQ:AKROAkero Therapeutics Inc
13/11/202306:00GlobeNewswire Inc.Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:AKROAkero Therapeutics Inc
10/11/202307:57GlobeNewswire Inc.Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023NASDAQ:AKROAkero Therapeutics Inc
08/11/202306:00GlobeNewswire Inc.Akero Therapeutics to Present at Upcoming Healthcare Conferences in NovemberNASDAQ:AKROAkero Therapeutics Inc
17/10/202315:05GlobeNewswire Inc.Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor ConferenceNASDAQ:AKROAkero Therapeutics Inc
10/10/202306:00GlobeNewswire Inc.Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and LipoNASDAQ:AKROAkero Therapeutics Inc
09/10/202315:05GlobeNewswire Inc.Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASHNASDAQ:AKROAkero Therapeutics Inc
04/10/202307:00GlobeNewswire Inc.Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & HepatologyNASDAQ:AKROAkero Therapeutics Inc
31/08/202306:00GlobeNewswire Inc.Akero Therapeutics to Present at Upcoming Healthcare Conferences in SeptemberNASDAQ:AKROAkero Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:AKRO

Su Consulta Reciente

USOTC
RBSH
Rebus (CE)
CEGG
XRPBTC
UNSW
TITTERETH
Titter
BIT
3EUS
WisdomTree EURO STOXX 50...
NASDAQ
FSIKX
Fidelity Sustainable Int...
DBI
I1HZ
MDAX ESG
BOV
L1CA34Q
Laboratory Corp of America
LSE
49DN
Mound Fin.4 3ca
BOV
LREN3R
LOJAS RENNER ON
BOV
L1UL34Q
Lululemon Athletica
USOTC
DUTV
Digital Utilities Ventures (PK)
USOTC
DREM
Dream Homes and Developm... (PK)
USOTC
UNRV
Unrivaled Brands (QB)
EU
IDNRA
AMUNDI DNRA INAV
COIN
YACHTXUST
YachtX
NYSE
VVR
Invesco Senior Income
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados